Charles Ryan, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Charles Ryan, MD

Professor of Clinical Medicine and Urology, Department of Medicine, UCSF
Program Leader, Genitourinary Medical Oncology, UCSF

Thomas Perkins Distinguished Professor in Cancer Research, UCSF

Phone: (415) 353-7171 (appts, urology); (415) 885-3882 (appts, thoracic)
Box 3211, UCSF
San Francisco, CA 94143-3211

View on UCSF Profiles

Cancer Center Membership

Program Member » Prostate Cancer

Research Summary

Charles J. Ryan, MD is an Associate Professor of Medicine and Urology at the UCSF Helen Diller Family Comprehensive Cancer Center. where he the Clinical Program Leader for Genitourinary Medical Oncology. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.

His clinical practice focuses predominantly on advanced prostate cancer as well as germ cell (testicular) tumors and other malignancies of the genitourinary tract.

His clinical and research work centers on the design and conduct of clinical trials of novel therapies for advanced prostate cancer, specifically secondary hormonal therapies targeting adrenal androgen signaling, insulin growth factor inhibitors, androgen receptor targeted therapy and chemotherapy. In addition to clinical trials Dr Ryan collaborates with many laboratories researching the role of the androgen receptor and other signaling mechanisms in prostate cancer patients.

Dr Ryan is a member of several honor societies and is the recipient of a Leadership and Service Award and the John Kimberly Curtis Award from the University of Wisconsin Medical School. He received the American College of Physicians/ American Society of Internal Medicine Evergreen Award in 2000 and the American Society of Clinical Oncology Merit Award and Cancer And Leukemia Group B: Young Investigator Award, both in 2003. He was awarded the Donald Coffey Career Development Award from the Prostate Cancer Foundation in 2006, a California Coalition to Cure Prostate Cancer Award in 2007 and received the Mentor Award from the Division of Hematology/Oncology in 2011.

Education

Marquette University, BA, 1991, Philosophy
University of Wisconsin - Madison, MD, 1996, Medicine
University of Wisconsin Hospital and Clinics, 1996-97, Intern, Medicine
University of Wisconsin Hospital and Clinics, 1997-99, Resident, Medicine
University of Wisconsin Hospital and Clinics, 1999-00, Chief Resident, Medicine
Memorial Sloan-Kettering Cancer Center, 2000-03, Fellow, Medical Oncology


Professional Experience

  • 2003-2008
    Assistant Clinical Professor of Medicine, UC San Francisco
  • 2008-2014
    Associate Clinical Professor of Medicine, UC San Francisco
  • 2014-present
    Professor of Clinical Medicine and Urology, UC San Francisco

Honors & Awards

  • 1991
    Alpha Sigma Nu, National Jesuit University Academic Honor Society
  • 1991
    Phi Beta Kappa, Marquette University
  • 1994
    Leadership and Service Award, University of Wisconsin Medical School
  • 1996
    John Kimberly Curtis Award, University of Wisconsin Medical School
  • 2000
    Evergreen Award, American College of Physicians-American Society of Internal Medicine
  • 2002
    ASCO Merit Award
  • 2002
    Cancer And Leukemia Group B Young Investigator Award
  • 2006
    Prostate Cancer Foundation: Donald Coffey Career Development Award
  • 2007
    California Coalition to Cure Prostate Cancer Award

Selected Publications

  1. Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. J Comp Eff Res. 2016 Jan; 5(1):5-7.
    View on PubMed
  2. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J Urol. 2015 Nov; 194(5):1277-84.
    View on PubMed
  3. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1.
    View on PubMed
  4. Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):772-99.
    View on PubMed
  5. Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. J Natl Compr Canc Netw. 2015 Jun; 13(6):811-22.
    View on PubMed
  6. Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7.
    View on PubMed
  7. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16.
    View on PubMed
  8. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res. 2015 Jul 15; 21(14):3170-7.
    View on PubMed
  9. Kidney cancer, version 3.2015. J Natl Compr Canc Netw. 2015 Feb; 13(2):151-9.
    View on PubMed
  10. Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. J Clin Oncol. 2015 Apr 20; 33(12):1356-63.
    View on PubMed
  11. Clinical cancer advances 2015: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2015 Mar 1; 33(7):786-809.
    View on PubMed
  12. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60.
    View on PubMed
  13. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res. 2015 Apr 1; 21(7):1621-7.
    View on PubMed
  14. Hair, hormones, and high-risk prostate cancer. J Clin Oncol. 2015 Feb 10; 33(5):386-7.
    View on PubMed
  15. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8.
    View on PubMed
  16. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014 Dec; 53(12):1149-60.
    View on PubMed
  17. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  18. Quo vadis: Advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer. 2015 Feb 1; 121(3):361-71.
    View on PubMed
  19. 'Heed not the oracle': risk assessment has no role in preventing suicide in schizophrenia. Acta Psychiatr Scand. 2014 Dec; 130(6):415-7.
    View on PubMed
  20. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist. 2014 Oct; 19(10):1012-8.
    View on PubMed

Go to UCSF Profiles, powered by CTSI